|
KR20190039347A
(ko)
*
|
2010-06-03 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
활성제의 전달을 위한 생분해성 지질
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
AU2012347605B2
(en)
*
|
2011-12-07 |
2017-09-21 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
WO2014089239A1
(en)
*
|
2012-12-07 |
2014-06-12 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US10195291B2
(en)
|
2013-09-24 |
2019-02-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
EP3083556B1
(en)
|
2013-12-19 |
2019-12-25 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
US10426737B2
(en)
|
2013-12-19 |
2019-10-01 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US11406742B2
(en)
|
2014-07-18 |
2022-08-09 |
M.A. Med Alliance SA |
Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
|
|
US9492594B2
(en)
|
2014-07-18 |
2016-11-15 |
M.A. Med Alliance SA |
Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
KR101882634B1
(ko)
*
|
2014-08-07 |
2018-07-26 |
다케다 야쿠힝 고교 가부시키가이샤 |
양이온성 지질
|
|
US10125092B2
(en)
|
2014-09-05 |
2018-11-13 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
US10081598B2
(en)
|
2014-12-26 |
2018-09-25 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
EP3275448B1
(en)
|
2015-03-24 |
2025-10-29 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
WO2017117528A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
WO2017222016A1
(ja)
*
|
2016-06-24 |
2017-12-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
CN110402145A
(zh)
|
2016-10-26 |
2019-11-01 |
莫得纳特斯公司 |
用于增强免疫应答的信使核糖核酸及其使用方法
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
EP4186888B1
(en)
|
2017-03-15 |
2025-11-26 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
EP3596112A2
(en)
|
2017-03-17 |
2020-01-22 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
|
US11485972B2
(en)
|
2017-05-18 |
2022-11-01 |
Modernatx, Inc. |
Modified messenger RNA comprising functional RNA elements
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
*
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
JP6826014B2
(ja)
*
|
2017-09-13 |
2021-02-03 |
株式会社東芝 |
生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
CA3079428A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
US11939601B2
(en)
|
2017-11-22 |
2024-03-26 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
EP3714045A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
EP3733647B1
(en)
|
2017-12-27 |
2022-06-15 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
TWI894123B
(zh)
|
2017-12-27 |
2025-08-21 |
日商武田藥品工業有限公司 |
含核酸之脂質奈米粒子及其用途
|
|
MA51523A
(fr)
|
2018-01-05 |
2020-11-11 |
Modernatx Inc |
Polynucléotides codant pour des anticorps anti-virus du chikungunya
|
|
EP3773745A1
(en)
|
2018-04-11 |
2021-02-17 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2019226650A1
(en)
|
2018-05-23 |
2019-11-28 |
Modernatx, Inc. |
Delivery of dna
|
|
JP7488193B2
(ja)
*
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
AU2019293286A1
(en)
|
2018-06-28 |
2021-01-07 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
CN111164068B
(zh)
*
|
2018-08-21 |
2023-11-14 |
株式会社东芝 |
生物降解性化合物、脂质粒子、含有脂质粒子的组合物、及试剂盒
|
|
WO2020047201A1
(en)
|
2018-09-02 |
2020-03-05 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
MX2021003015A
(es)
|
2018-09-13 |
2021-07-15 |
Modernatx Inc |
Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
|
|
WO2020056155A2
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
|
JP2022500444A
(ja)
|
2018-09-14 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
|
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3856233A1
(en)
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
CA3114435A1
(en)
|
2018-10-01 |
2020-04-09 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US20220009878A1
(en)
*
|
2018-10-02 |
2022-01-13 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
CN114127044A
(zh)
*
|
2019-04-25 |
2022-03-01 |
英特利亚治疗股份有限公司 |
可电离的胺类脂质和脂质纳米颗粒
|
|
JP2022532078A
(ja)
|
2019-05-08 |
2022-07-13 |
アストラゼネカ アクチボラグ |
皮膚及び創傷のための組成物並びにその使用の方法
|
|
MA55899A
(fr)
|
2019-05-08 |
2022-03-16 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmalonique
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
JP7759311B2
(ja)
|
2019-07-19 |
2025-10-23 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
リコンビナーゼ組成物及び使用方法
|
|
JP7769325B2
(ja)
|
2019-07-23 |
2025-11-13 |
株式会社東芝 |
Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
|
|
CA3145913A1
(en)
|
2019-07-29 |
2021-02-04 |
James Everett Dahlman |
Nanomaterials containing constrained lipids and uses thereof
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
CN114502204A
(zh)
|
2019-08-14 |
2022-05-13 |
库尔维科公司 |
具有降低的免疫刺激性质的rna组合和组合物
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
IL294318A
(en)
|
2020-01-09 |
2022-08-01 |
Guide Therapeutics Llc |
Nanomaterials
|
|
KR20220144416A
(ko)
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
GB2613225B
(en)
|
2020-03-04 |
2024-01-03 |
Verve Therapeutics Inc |
Compositions and methods for targeted RNA delivery
|
|
CA3173528A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
JP2023520763A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
|
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
US12188060B2
(en)
|
2020-05-15 |
2025-01-07 |
Crispr Therapeutics Ag |
Messenger RNA encoding Cas9 for use in genome-editing systems
|
|
IL298362A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Coronavirus antigen compositions and their uses
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
WO2021243301A2
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
KR20230029685A
(ko)
|
2020-05-29 |
2023-03-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
Trem 조성물 및 이에 관련된 방법
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
EP4158005A1
(en)
|
2020-06-01 |
2023-04-05 |
ModernaTX, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
CA3181680A1
(en)
|
2020-06-12 |
2021-12-16 |
University Of Rochester |
Encoding and expression of ace-trnas
|
|
IL299094A
(en)
|
2020-06-15 |
2023-02-01 |
Res Inst Nationwide Childrens Hospital |
Administration of an adeno-associated virus vector for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
JP2023535632A
(ja)
|
2020-07-27 |
2023-08-18 |
アンジャリウム バイオサイエンシズ エージー |
Ｄｎａ分子の組成物、その作製方法、及びその使用方法
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
MA71659A
(fr)
|
2020-08-06 |
2025-05-30 |
Modernatx, Inc. |
Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
AU2021336976A1
(en)
|
2020-09-03 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
WO2022104131A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
EP4255888A4
(en)
*
|
2020-12-02 |
2024-12-04 |
Merck Sharp & Dohme LLC |
LIPID DNANOPARTICLE COMPOSITIONS WITH CATIONIC MONOESTER LIPIDS
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
EP4281080A4
(en)
|
2021-01-20 |
2025-09-24 |
Beam Therapeutics Inc |
NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
CA3213107A1
(en)
|
2021-03-23 |
2022-09-29 |
Mirko HENNIG |
Polynucleotide compositions, related formulations, and methods of use thereof
|
|
US20240216288A1
(en)
|
2021-03-24 |
2024-07-04 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
US20240226025A1
(en)
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
|
US20240207374A1
(en)
|
2021-03-24 |
2024-06-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
JP2024512780A
(ja)
|
2021-04-01 |
2024-03-19 |
モデルナティエックス インコーポレイテッド |
多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
EP4321524B1
(en)
*
|
2021-04-09 |
2025-12-10 |
Sogo Pharmaceutical Co., Ltd. |
Lipid and composition
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
KR20240008872A
(ko)
*
|
2021-05-06 |
2024-01-19 |
아크투루스 쎄라퓨틱스, 인크. |
Rna 전달을 위한 이온화 가능한 양이온성 지질
|
|
US20240263195A1
(en)
|
2021-05-11 |
2024-08-08 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
|
US20240269248A1
(en)
|
2021-05-19 |
2024-08-15 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
EP4355882A2
(en)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
US20240316165A1
(en)
|
2021-07-12 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023009499A1
(en)
|
2021-07-27 |
2023-02-02 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
|
WO2023015223A2
(en)
|
2021-08-03 |
2023-02-09 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
JP2024528983A
(ja)
|
2021-08-04 |
2024-08-01 |
モデルナティエックス インコーポレイテッド |
キメラ代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
US20240398940A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
MX2024003262A
(es)
|
2021-09-17 |
2024-06-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para producir poliribonucleotidos circulares.
|
|
US20250281596A1
(en)
*
|
2021-09-28 |
2025-09-11 |
Seqirus Inc. |
Ionizable cationic compound
|
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
US20250041393A1
(en)
|
2021-11-01 |
2025-02-06 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
|
EP4426828A1
(en)
|
2021-11-01 |
2024-09-11 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
CN118829423A
(zh)
|
2021-11-12 |
2024-10-22 |
摩登纳特斯有限公司 |
用于将有效载荷分子递送至气道上皮的组合物
|
|
JP2024542188A
(ja)
|
2021-11-16 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
AU2022390215B2
(en)
|
2021-11-18 |
2026-02-26 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
|
JP2024542260A
(ja)
|
2021-11-22 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
CN118401544A
(zh)
|
2021-11-24 |
2024-07-26 |
旗舰创业创新六公司 |
水痘-带状疱疹病毒免疫原组合物及其用途
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240118174A
(ko)
|
2021-12-17 |
2024-08-02 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
|
|
CA3241488A1
(en)
*
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2022420615A1
(en)
|
2021-12-22 |
2024-07-04 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
JP2025502599A
(ja)
*
|
2021-12-23 |
2025-01-28 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250345416A1
(en)
|
2022-01-27 |
2025-11-13 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
AU2023215397A1
(en)
|
2022-02-07 |
2024-08-22 |
University Of Rochester |
Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
|
|
EP4475882A1
(en)
|
2022-02-09 |
2024-12-18 |
ModernaTX, Inc. |
Mucosal administration methods and formulations
|
|
US20250213664A1
(en)
|
2022-02-18 |
2025-07-03 |
Modernatx, Inc. |
Mrnas encoding checkpoint cancer vaccines and uses thereof
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
US20250221931A1
(en)
|
2022-03-25 |
2025-07-10 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
CN116354836A
(zh)
*
|
2022-03-25 |
2023-06-30 |
深圳市新合生物医疗科技有限公司 |
阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
EP4508242A1
(en)
|
2022-04-11 |
2025-02-19 |
ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
CN116969851A
(zh)
*
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
CN115850104B
(zh)
*
|
2022-04-29 |
2023-07-18 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
CN115887674B
(zh)
|
2022-04-29 |
2023-08-25 |
北京剂泰医药科技有限公司 |
脂质纳米颗粒
|
|
EP4332087A1
(en)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid nanoparticles
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
EP4525830A1
(en)
|
2022-05-17 |
2025-03-26 |
ModernaTX, Inc. |
Preparation of highly concentrated mrna
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
JP2025522297A
(ja)
|
2022-05-25 |
2025-07-15 |
ビオンテック エスエー |
サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
EP4536197A1
(en)
|
2022-06-07 |
2025-04-16 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4540288A1
(en)
|
2022-06-20 |
2025-04-23 |
CRISPR Therapeutics AG |
Cd117-targeting nanoparticles for use in drug delivery
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
WO2023250119A1
(en)
|
2022-06-24 |
2023-12-28 |
Modernatx, Inc. |
Methods of producing rna
|
|
CN114874106B
(zh)
*
|
2022-07-11 |
2023-04-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其制备方法和应用
|
|
JP2025525569A
(ja)
|
2022-07-18 |
2025-08-05 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
遺伝子編集成分、システム、及び使用方法
|
|
CA3260437A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
NANOMATERIALS INCLUDING TRIOLS
|
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
|
AU2023316579A1
(en)
|
2022-07-29 |
2025-02-13 |
Fujifilm Corporation |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
|
|
EP4565604A2
(en)
|
2022-08-01 |
2025-06-11 |
Flagship Pioneering Innovations VII, LLC |
Immunomodulatory proteins and related methods
|
|
WO2024031051A1
(en)
*
|
2022-08-05 |
2024-02-08 |
Life Technologies Corporation |
Lipids for nucleic acid delivery
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20260060926A1
(en)
|
2022-08-31 |
2026-03-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
IL319704A
(en)
|
2022-09-23 |
2025-05-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of HBV gene expression
|
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
JP2025533527A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN117800859A
(zh)
*
|
2022-09-26 |
2024-04-02 |
苏州科锐迈德生物医药科技有限公司 |
具有戊二酸骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074634A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
EP4626400A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4630057A1
(en)
|
2022-12-08 |
2025-10-15 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
EP4385523A1
(en)
|
2022-12-14 |
2024-06-19 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid-based topical injection formulations
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
WO2024131832A1
(zh)
*
|
2022-12-20 |
2024-06-27 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
CN121263401A
(zh)
|
2022-12-22 |
2026-01-02 |
内诺维什疗法股份有限公司 |
用于递送核酸和其他治疗剂的含硫的可电离脂质
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4649087A2
(en)
|
2023-01-11 |
2025-11-19 |
Engage Biologics Inc. |
Non-viral expression systems and methods of use thereof
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
WO2024156291A1
(en)
*
|
2023-01-29 |
2024-08-02 |
Geneditbio Limited |
Cationic lipids and lipid nanoparticles
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
TW202449152A
(zh)
|
2023-02-09 |
2024-12-16 |
美商艾拉倫製藥股份有限公司 |
Ｒｅｖｅｒｓｉｒ分子及其使用方法
|
|
CN120813562A
(zh)
*
|
2023-02-09 |
2025-10-17 |
斯奇络斯公司 |
可离子化阳离子化合物
|
|
CN121263425A
(zh)
|
2023-02-13 |
2026-01-02 |
旗舰创业创新第七有限责任公司 |
含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
WO2024182301A2
(en)
|
2023-02-27 |
2024-09-06 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
CN121358494A
(zh)
|
2023-03-15 |
2026-01-16 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206835A1
(en)
|
2023-03-30 |
2024-10-03 |
Modernatx, Inc. |
Circular mrna and production thereof
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
AU2024260120A1
(en)
|
2023-04-27 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
EP4704816A1
(en)
|
2023-05-03 |
2026-03-11 |
ModernaTX, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2024228150A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
EP4705481A2
(en)
|
2023-05-05 |
2026-03-11 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
AU2024303397B2
(en)
|
2023-06-16 |
2026-03-26 |
Beijing Jitai Life Sciences Ltd |
Rapidly-metabolized lipid compound
|
|
KR20260032546A
(ko)
*
|
2023-06-16 |
2026-03-09 |
아퀴타스 테라퓨틱스 인크. |
아미드 포함 지질
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
IL325865A
(en)
|
2023-07-21 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
KR20260049597A
(ko)
|
2023-08-04 |
2026-04-14 |
알닐람 파마슈티칼스 인코포레이티드 |
Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
CN117088820B
(zh)
*
|
2023-08-18 |
2025-11-28 |
苏州信使生物科技有限公司 |
一种新型阳离子lnp递送系统及制备方法
|
|
WO2025042806A2
(en)
|
2023-08-21 |
2025-02-27 |
Modernatx, Inc. |
C-met binding antibodies, nucleic acids encoding same, and methods of use
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
IL326647A
(en)
|
2023-09-01 |
2026-04-01 |
Novoarc Gmbh |
Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025059290A1
(en)
|
2023-09-14 |
2025-03-20 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025077836A1
(en)
*
|
2023-10-13 |
2025-04-17 |
Beigene Switzerland Gmbh |
Ionizable lipids and lipid nanoparticles for rna delivery
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025101685A1
(en)
|
2023-11-09 |
2025-05-15 |
University Of Rochester |
Suppression of nonsense mutations using anticodon engineered (ace)-trnas
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2025111297A1
(en)
|
2023-11-21 |
2025-05-30 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12553042B2
(en)
|
2023-12-01 |
2026-02-17 |
Recode Therapeutics, Inc. |
Method for quantifying an amount of capped messenger RNA
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
CN119143714B
(zh)
*
|
2023-12-11 |
2025-06-10 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物和脂质纳米颗粒
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
EP4677108A1
(en)
|
2024-04-22 |
2026-01-14 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025255199A1
(en)
|
2024-06-05 |
2025-12-11 |
Modernatx, Inc. |
Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026030209A1
(en)
|
2024-07-29 |
2026-02-05 |
University Of Rochester |
Use of decoding trnas to boost protein expression or function
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026044055A1
(en)
|
2024-08-23 |
2026-02-26 |
Modernatx, Inc. |
Muc16 binding molecules, nucleic acids encoding same, and methods of use
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
WO2026075820A1
(en)
|
2024-10-03 |
2026-04-09 |
Modernatx, Inc. |
4-1bb binding molecules, nucleic acids encoding same, and methods of use
|
|
WO2026078565A1
(en)
|
2024-10-10 |
2026-04-16 |
Crispr Therapeutics Ag |
Messenger rna encoding cas9 for use in genome-editing systems
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026085234A1
(en)
|
2024-10-18 |
2026-04-23 |
Modernatx, Inc. |
3' untranslated region sequences for extending messenger ribonucleic acids half-life
|